Pandit Lekha
Centre for Advanced Neurological Research, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India.
Ann Indian Acad Neurol. 2025 Jan 1;28(1):10-16. doi: 10.4103/aian.aian_728_24. Epub 2025 Jan 24.
Myelin oligodendrocyte glycoprotein antibody-associated disease has been recently identified to be a distinct autoimmune central nervous system disorder. There is significant clinical and radiological overlap with multiple sclerosis and aquaporin-4-IgG-associated neuromyelitis optica spectrum disorders. Clinical course is variable in that patients may have a monophasic or relapsing course, disease severity is unpredictable, and unlike other idiopathic autoimmune inflammatory disorders, there is no gender predilection and it is more likely to affect pediatric population. There are no clear-cut treatment guidelines. Duration and dose of oral steroids after the first attack, role of immunosuppressants in relapsing disease, and duration of therapy for the latter are not certain. Currently, there are no disease-specific therapies available, though some novel therapies are under trial. Some of these challenges will be addressed in this paper.
髓鞘少突胶质细胞糖蛋白抗体相关疾病最近被确定为一种独特的自身免疫性中枢神经系统疾病。它在临床和影像学上与多发性硬化症以及水通道蛋白4-IgG相关的视神经脊髓炎谱系障碍有显著重叠。临床病程多变，患者可能有单相或复发病程，疾病严重程度不可预测，与其他特发性自身免疫性炎症性疾病不同，该病无性别倾向，且更易累及儿童群体。目前尚无明确的治疗指南。首次发作后口服类固醇的疗程和剂量、免疫抑制剂在复发疾病中的作用以及后者的治疗持续时间均不明确。目前尚无针对该疾病的特效疗法，不过一些新疗法正在试验中。本文将探讨其中的一些挑战。
